Fund 13F filing

Point72 cut $68.2M of Supernus Pharmaceuticals, Inc. (SUPN) stock

SEC Form 13F · Filed Aug 14, 2026

Point72 cut $68.2M of Supernus Pharmaceuticals, Inc. (SUPN) stock in the quarter ending Jun 30, 2026, per a 13F filed Aug 14, 2026.

A 13F shows holdings at quarter end, so the exact trade dates are not disclosed.

Sold

Supernus Pharmaceuticals, Inc.

Value

$68.2M

Share this trade

From a public SEC Form 13F, linked above. Not investment advice, and not a recommendation to buy or sell.